Alnylam Pharmaceuticals (ALNY) EBIT Margin Growth (5y) (2014 - 2026)
Powered by 
Analysis
Alnylam Pharmaceuticals (ALNY) EBIT Margin Growth (5y) (2014 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn |
| 10 | Incyte | 25.59 Bn | 21.05 Bn | 1.57 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 8,420.00 |
| Mar 31, 2026 | 12,791.00 |
| Dec 31, 2025 | 13,075.00 |
| Sep 30, 2025 | 20,840.00 |
| Jun 30, 2025 | 18,919.00 |
| Mar 31, 2025 | 27,152.00 |
| Dec 31, 2024 | 39,810.00 |
| Sep 30, 2024 | 29,338.00 |
| Jun 30, 2024 | 53,577.00 |
| Mar 31, 2024 | 55,825.00 |
| Dec 31, 2023 | 102,120.00 |
| Sep 30, 2023 | 1.23 Mn |
| Jun 30, 2023 | 57,107.00 |
| Mar 31, 2023 | 62,619.00 |
| Dec 31, 2022 | 33,212.00 |
| Sep 30, 2022 | 63,822.00 |
| Jun 30, 2022 | 67,091.00 |
| Mar 31, 2022 | 49,296.00 |
| Dec 31, 2021 | 58,610.00 |
| Sep 30, 2021 | 68,463.00 |